410 related articles for article (PubMed ID: 32641750)
1. Sex differences in SARS-CoV-2 infection rates and the potential link to prostate cancer.
Chakravarty D; Nair SS; Hammouda N; Ratnani P; Gharib Y; Wagaskar V; Mohamed N; Lundon D; Dovey Z; Kyprianou N; Tewari AK
Commun Biol; 2020 Jul; 3(1):374. PubMed ID: 32641750
[TBL] [Abstract][Full Text] [Related]
2. COVID-19 and the male susceptibility: the role of ACE2, TMPRSS2 and the androgen receptor.
Mjaess G; Karam A; Aoun F; Albisinni S; Roumeguère T
Prog Urol; 2020 Sep; 30(10):484-487. PubMed ID: 32620366
[TBL] [Abstract][Full Text] [Related]
3. Male predisposition to severe COVID-19: Review of evidence and potential therapeutic prospects.
Acheampong DO; Barffour IK; Boye A; Aninagyei E; Ocansey S; Morna MT
Biomed Pharmacother; 2020 Nov; 131():110748. PubMed ID: 33152916
[TBL] [Abstract][Full Text] [Related]
4. Spironolactone may provide protection from SARS-CoV-2: Targeting androgens, angiotensin converting enzyme 2 (ACE2), and renin-angiotensin-aldosterone system (RAAS).
Cadegiani FA; Goren A; Wambier CG
Med Hypotheses; 2020 Oct; 143():110112. PubMed ID: 32721806
[TBL] [Abstract][Full Text] [Related]
5. The lysosome: A potential juncture between SARS-CoV-2 infectivity and Niemann-Pick disease type C, with therapeutic implications.
Ballout RA; Sviridov D; Bukrinsky MI; Remaley AT
FASEB J; 2020 Jun; 34(6):7253-7264. PubMed ID: 32367579
[TBL] [Abstract][Full Text] [Related]
6. Why are women better protected from COVID-19: Clues for men? Sex and COVID-19.
Elgendy IY; Pepine CJ
Int J Cardiol; 2020 Sep; 315():105-106. PubMed ID: 32418736
[No Abstract] [Full Text] [Related]
7. Strategies for Targeting SARS CoV-2: Small Molecule Inhibitors-The Current Status.
Beeraka NM; Sadhu SP; Madhunapantula SV; Rao Pragada R; Svistunov AA; Nikolenko VN; Mikhaleva LM; Aliev G
Front Immunol; 2020; 11():552925. PubMed ID: 33072093
[TBL] [Abstract][Full Text] [Related]
8. Molecular mechanisms and epidemiology of COVID-19 from an allergist's perspective.
Hosoki K; Chakraborty A; Sur S
J Allergy Clin Immunol; 2020 Aug; 146(2):285-299. PubMed ID: 32624257
[TBL] [Abstract][Full Text] [Related]
9. Scaffold morphing of arbidol (umifenovir) in search of multi-targeting therapy halting the interaction of SARS-CoV-2 with ACE2 and other proteases involved in COVID-19.
Choudhary S; Silakari O
Virus Res; 2020 Nov; 289():198146. PubMed ID: 32866534
[TBL] [Abstract][Full Text] [Related]
10. COVID-19 and androgen-targeted therapy for prostate cancer patients.
Bhowmick NA; Oft J; Dorff T; Pal S; Agarwal N; Figlin RA; Posadas EM; Freedland SJ; Gong J
Endocr Relat Cancer; 2020 Sep; 27(9):R281-R292. PubMed ID: 32508311
[TBL] [Abstract][Full Text] [Related]
11. COVID-19 and Kidney Disease: Molecular Determinants and Clinical Implications in Renal Cancer.
Mihalopoulos M; Dogra N; Mohamed N; Badani K; Kyprianou N
Eur Urol Focus; 2020 Sep; 6(5):1086-1096. PubMed ID: 32540268
[TBL] [Abstract][Full Text] [Related]
12. SARS-CoV-2: characteristics and current advances in research.
Yang Y; Xiao Z; Ye K; He X; Sun B; Qin Z; Yu J; Yao J; Wu Q; Bao Z; Zhao W
Virol J; 2020 Jul; 17(1):117. PubMed ID: 32727485
[TBL] [Abstract][Full Text] [Related]
13. Potential therapeutic targets and promising drugs for combating SARS-CoV-2.
Zhou H; Fang Y; Xu T; Ni WJ; Shen AZ; Meng XM
Br J Pharmacol; 2020 Jul; 177(14):3147-3161. PubMed ID: 32368792
[TBL] [Abstract][Full Text] [Related]
14. Are there any Therapeutic Options Currently Available for Wuhan Coronavirus?
Carradori S
Antiinflamm Antiallergy Agents Med Chem; 2020; 19(2):85-87. PubMed ID: 32213152
[No Abstract] [Full Text] [Related]
15. Could a specific ACE2 activator drug improve the clinical outcome of SARS-CoV-2? A potential pharmacological insight.
Nicolau LAD; Nolêto IRSG; Medeiros JVR
Expert Rev Clin Pharmacol; 2020 Aug; 13(8):807-811. PubMed ID: 32686527
[No Abstract] [Full Text] [Related]
16. Current pharmacological modalities for management of novel coronavirus disease 2019 (COVID-19) and the rationale for their utilization: A review.
Giovane RA; Rezai S; Cleland E; Henderson CE
Rev Med Virol; 2020 Sep; 30(5):e2136. PubMed ID: 32644275
[TBL] [Abstract][Full Text] [Related]
17. Potential COVID-19 therapeutics from a rare disease: weaponizing lipid dysregulation to combat viral infectivity.
Sturley SL; Rajakumar T; Hammond N; Higaki K; Márka Z; Márka S; Munkacsi AB
J Lipid Res; 2020 Jul; 61(7):972-982. PubMed ID: 32457038
[TBL] [Abstract][Full Text] [Related]
18. Candidate drugs against SARS-CoV-2 and COVID-19.
McKee DL; Sternberg A; Stange U; Laufer S; Naujokat C
Pharmacol Res; 2020 Jul; 157():104859. PubMed ID: 32360480
[TBL] [Abstract][Full Text] [Related]
19. COVID-19 and Individual Genetic Susceptibility/Receptivity: Role of ACE1/ACE2 Genes, Immunity, Inflammation and Coagulation. Might the Double X-chromosome in Females Be Protective against SARS-CoV-2 Compared to the Single X-Chromosome in Males?
Gemmati D; Bramanti B; Serino ML; Secchiero P; Zauli G; Tisato V
Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32423094
[TBL] [Abstract][Full Text] [Related]
20. A Replication-Competent Vesicular Stomatitis Virus for Studies of SARS-CoV-2 Spike-Mediated Cell Entry and Its Inhibition.
Dieterle ME; Haslwanter D; Bortz RH; Wirchnianski AS; Lasso G; Vergnolle O; Abbasi SA; Fels JM; Laudermilch E; Florez C; Mengotto A; Kimmel D; Malonis RJ; Georgiev G; Quiroz J; Barnhill J; Pirofski LA; Daily JP; Dye JM; Lai JR; Herbert AS; Chandran K; Jangra RK
Cell Host Microbe; 2020 Sep; 28(3):486-496.e6. PubMed ID: 32738193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
